Dual therapy with tofacitinib and steroids for acute severe ulcerative colitis: a randomized double-blind placebo-controlled trial

托法替尼 医学 溃疡性结肠炎 内科学 随机对照试验 安慰剂 不利影响 结肠切除术 胃肠病学 外科 疾病严重程度 临床试验
作者
Umang Arora,Mahak Verma,Divya Madan,Mukesh Singh,Devasenathipathy Kandasamy,Himanshu Narang,Manjeet Goyal,Mridul Mahajan,Sandeep Kumar Mundhra,Shubham Prasad,Malambo Mubunnu,Ankur Goyal,Rajesh Panwar,Tushar Sehgal,Nihar Ranjan Dash,Raju Sharma,Vaishali Bhardwaj,Saurabh Kedia,Govind Kumar Makharia,Rishabh Bose
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:20 (10)
标识
DOI:10.1093/ecco-jcc/jjag149
摘要

BACKGROUND: One-third of patients with acute severe ulcerative colitis (ASUC) fail intravenous corticosteroids. We evaluated whether adding tofacitinib to corticosteroids reduces treatment failure in ASUC. METHODS: In this single-center, double-blind, placebo-controlled trial, adults with ASUC were randomized 1:1 to tofacitinib (10 mg three times daily for 3 days, then twice daily) or placebo for 5 days alongside corticosteroids. Primary outcome was treatment failure at day 6 (<3-point Lichtiger reduction or total score ≥10, or colectomy). Secondary outcomes were relapse (≥3-point rise with total ≥10), rescue therapy, and colectomy at 90 days. Modified intention-to-treat analysis was performed. (CTRI/2022/11/047186). RESULTS: Of 62 randomized patients, 58 were analyzed: 33 in the tofacitinib arm and 25 in the placebo arm. The trial was terminated early because of slow recruitment and did not reach the planned sample size of 98. Day 6 treatment failure was numerically lower with tofacitinib in unadjusted analysis (24.2% vs 36.0%; RR 0.67, 95% CI 0.30-1.51; P = .33) and significantly lower after adjustment for baseline covariate imbalance (adjusted RR 0.47, 95% CI 0.24-0.93; P = .03). At 90 days, colectomy rates were similar (12.1% vs 12.0%; P = 1.0), but more tofacitinib-treated patients remained on assigned therapy (84.4% vs 54.2%) and rescue therapy was lower (HR 0.27, 95% CI 0.09-0.78; P = .01). Serious adverse events occurred in one versus three patients. No deaths occurred with tofacitinib versus two deaths with placebo. CONCLUSION: Dual therapy with tofacitinib and steroids in ASUC did not significantly reduce treatment failure at day 6, unless adjustment for baseline imbalance in serum albumin was taken into account. It reduced the need for rescue therapy over 90 days without affecting colectomy risk. Larger clinical trials are required to confirm these findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜美无剑发布了新的文献求助10
刚刚
1秒前
zhuzhenghua发布了新的文献求助20
1秒前
bkagyin的应助被自由的纲采纳,获得10
2秒前
3秒前
KerwinLLL发布了新的文献求助10
4秒前
5秒前
万能图书馆的应助被吹走霉运采纳,获得10
5秒前
lmhytr完成签到,获得积分10
5秒前
科研通AI6.4的应助被和平发展采纳,获得10
5秒前
6秒前
隐形曼青的应助被北大落榜生采纳,获得10
6秒前
7秒前
7秒前
7秒前
8秒前
华仔的应助被科研通管家采纳,获得10
8秒前
蓝天的应助被科研通管家采纳,获得10
8秒前
贵医实验王粥张完成签到,获得积分10
8秒前
SciGPT的应助被科研通管家采纳,获得10
8秒前
8秒前
完美世界的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
今后的应助被科研通管家采纳,获得10
9秒前
9秒前
渡人舟的应助被科研通管家采纳,获得10
9秒前
9秒前
上官若男的应助被科研通管家采纳,获得10
9秒前
CodeCraft的应助被科研通管家采纳,获得10
9秒前
9秒前
orixero的应助被科研通管家采纳,获得10
9秒前
9秒前
FashionBoy的应助被科研通管家采纳,获得10
9秒前
李健的应助被科研通管家采纳,获得10
9秒前
10秒前
10秒前
大个的应助被甜心椰奶莓莓采纳,获得10
10秒前
10秒前
HopeStar发布了新的文献求助10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170866
求助须知:如何正确求助?哪些是违规求助? 9563691
关于积分的说明 21771699
捐赠科研通 7762353
什么是DOI,文献DOI怎么找? 3430767
关于科研通互助平台的介绍 2554622
邀请新用户注册赠送积分活动 2475597